Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages: A propensity score analysis
- ,
- Bryan Valcarcel,
- Zaida Morante,
- Mecker G. Möller,
- Sofia Lizandro,
- Lia P. Rebaza
- ,
- Universidad Científica del Sur,
- Instituto Nacional de Enfermedades Neoplásicas,
- University of Miami Miller School of Medicine,
- Sociedad Científica de Estudiantes de Medicina de la Universidad Científica del Sur,
- Hospital Nacional Dos de Mayo
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 29-35 (7 pages)Journal (Volume, Issue Number)
Breast Disease (Volume 39, Issue 1)Publication milestones
- Published - 2020
Publication status
ISSN
0888-6008Publication IDs
- Scopus: 85079780845
- PubMed: 31903977
Abstract
BACKGROUND: Breast-conserving surgery (BCS) as an alternative to total mastectomy (TM) in patients with early-stage triple-negative breast cancer (TNBC) is not widely spread. OBJECTIVE: We aimed to compare the overall survival (OS) and disease-free survival (DFS) between both surgical approaches in early-stage TNBC patients at 10 years. METHODS: We conducted a retrospective cohort study in TNBC female patients with stage I-IIa, treated at a single-center during the period of 2000-2014. We estimated and compared the survival rates with the Kaplan Meier and Long-rank test. Propensity scores were calculated with the generalized boosted regression model and were used in the multivariate Cox regression analysis with the covariate adjustment method. RESULTS: We included 288 patients, 111 in the BCS vs. 177 in the TM group. The median follow-up was 102 months. Moreover, the patients in the BCS group had superior OS (85% vs. 81%, p = 0.56) and DFS (83% vs. 80%, p = 0.42) at 10 years. In the multivariate Cox analysis, BCS decreased the mortality risk (HR: 0.79, 95% CI: 0.37-1.67, p = 0.538), and the locoregional or distant recurrence risk (HR: 0.67, 95% CI: 0.32-1.41, p = 0.294), albeit with no statistical significance. CONCLUSION: BCS is a safe alternative to TM in Latin-American patients with early-stage TNBC.
Funding Details
Access to documents
Publication metrics
Metrics
PlumX, opens in new tab
Sustainable Development Goals
- SDG 3 Good Health and Well
